Biological Equivalence: The Forgotten Third Pillar

Written by HATEM RABEH, MD, MSc Ing

Your Clinical Evaluation Expert And Partner

in
S

The problem is not that manufacturers ignore biological equivalence deliberately. The problem is that it does not appear obvious until someone with tissue contact experience looks at the claim.

By then, the CER is already submitted. The equivalence table is locked. And now you need to justify why you considered two materials biocompatible without demonstrating they are biologically equivalent.

The Three-Pillar Framework Nobody Completes

MDR Annex XIV Section 3 establishes the requirements for demonstrating equivalence. It requires technical, biological, and clinical equivalence. Three pillars. Equal importance.

Yet most equivalence demonstrations I review address only two.

Technical equivalence gets the most attention. Manufacturers compare specifications, materials, designs, energy outputs, mechanical properties. This part is usually thorough. Engineers understand this territory.

Clinical equivalence follows. Intended purpose, indications, patient population, duration of contact. This section is often adequate if the manufacturer understands what clinical characteristics actually matter for equivalence.

Then comes biological equivalence. This is where the gaps appear.

What Biological Equivalence Actually Means

Biological equivalence is not about passing the same biocompatibility tests. It is about demonstrating that two devices interact with biological tissues in the same way.

This sounds simple until you examine what it requires.

If your subject device uses a different polymer than the equivalent device, you need to show that both materials produce the same biological response. Not just that both are biocompatible. That they are equivalent in their biological behavior.

If your device contacts tissue for 30 days and the equivalent device contacts for 24 hours, you need to address whether prolonged contact creates different biological risks. Even if both meet ISO 10993 requirements for their respective contact durations.

If your device is coated and the equivalent device is not, you need to demonstrate that the coating does not change the biological interface in a way that affects safety or performance.

These are not academic questions. These are the questions that determine whether your equivalence claim survives regulatory scrutiny.

Why This Gets Overlooked

I have seen this pattern repeatedly. The clinical affairs specialist prepares the equivalence demonstration. They focus on clinical data because that is their domain. They assume biocompatibility is handled by the technical file team.

The technical team addresses biocompatibility testing. They ensure ISO 10993 compliance. They assume this satisfies the biological requirement.

No one explicitly demonstrates biological equivalence because no one is clearly responsible for it.

Then the Notified Body reviewer, who has seen this gap a hundred times before, asks for the biological equivalence justification. And the file goes into major non-conformity status.

What Breaks Biological Equivalence

Certain differences automatically trigger the need for deeper biological equivalence justification. Understanding these triggers helps you identify when your equivalence claim is at risk.

Material Differences

If your device uses different materials than the equivalent device, biological equivalence is not automatic. Even if both materials are biocompatible.

I reviewed a case where the subject device used a silicone formulation from a different supplier than the equivalent device. Same chemical family. Both tested to ISO 10993. The manufacturer assumed equivalence.

The reviewer did not. Different formulations can have different extractables, different surface properties, different tissue responses. The manufacturer had no data addressing this.

The solution was not to repeat all biocompatibility testing. The solution was to provide comparative chemical characterization and toxicological assessment showing that the formulation differences did not create different biological risks.

But this required additional work that delayed the submission by months.

Contact Duration Differences

ISO 10993-1 categorizes contact duration: limited (up to 24 hours), prolonged (24 hours to 30 days), permanent (more than 30 days). Each category has different testing requirements.

If your device falls into a different contact duration category than the equivalent device, you need to address this explicitly in your biological equivalence demonstration.

Simply stating that both are biocompatible is insufficient. The reviewer needs to understand why the difference in contact duration does not affect the applicability of clinical data from the equivalent device.

Contact Type or Location Differences

A device that contacts mucosal membranes may not be biologically equivalent to one that contacts intact skin, even if both are made from the same material.

A device implanted in bone may not be biologically equivalent to one implanted in soft tissue, even if the material composition is identical.

The biological environment matters. The tissue response matters. These differences affect whether clinical data from one device can be bridged to another.

How to Demonstrate Biological Equivalence Properly

Biological equivalence demonstration requires structured comparative analysis. Not assumptions. Not general statements about biocompatibility. Comparative analysis.

Start with a clear comparison table. List materials, contact type, contact duration, tissue interface characteristics, body location. Do this for both your device and the equivalent device.

Then address each difference explicitly.

When Materials Are Identical

If both devices use identical materials from identical suppliers with identical processing, biological equivalence is straightforward to demonstrate. State this clearly. Provide material specifications or certificates confirming identity.

This is the simplest scenario, but it requires documentation. You cannot simply assert material identity. You must demonstrate it.

When Materials Are Similar But Not Identical

This is where most biological equivalence demonstrations become inadequate.

You need comparative data. This could be:

• Chemical characterization showing similar composition and extractables profiles
• Surface analysis showing similar tissue-interface properties
• Comparative biocompatibility data showing similar biological responses
• Toxicological assessment showing similar risk profiles

The goal is to show that despite material differences, the biological interaction is equivalent. This requires evidence, not assertion.

In one case I reviewed, the manufacturer provided comparative cytotoxicity and sensitization data for two different polymer grades. The data showed comparable responses. Combined with chemical characterization showing similar extractables, this demonstrated biological equivalence despite the material difference.

The key was comparative evidence, not compliance statements.

When Contact Characteristics Differ

If your device has longer contact duration, you need to address whether this creates additional biological risks not covered by the equivalent device data.

This might involve:

• Reviewing your biocompatibility evaluation for the extended duration
• Assessing whether chronic exposure creates risks not present in shorter exposure
• Evaluating whether the clinical data from the equivalent device reasonably covers your extended duration scenario

Sometimes this analysis shows that the equivalent device data is sufficient. Sometimes it shows gaps that need to be filled with additional data or literature.

The important point is that you address it explicitly rather than hoping the reviewer does not notice.

The ISO 10993 Trap

I need to address this specifically because it appears in almost every insufficient biological equivalence demonstration I review.

ISO 10993 compliance does not demonstrate biological equivalence.

Let me say this again because it is critical: passing ISO 10993 tests demonstrates biocompatibility. It does not demonstrate equivalence.

Two devices can both be biocompatible without being biologically equivalent. The biological response to different materials can differ even when both responses fall within acceptable safety limits.

This is not a subtle regulatory interpretation. This is fundamental to what equivalence means.

When you write “both devices are ISO 10993 compliant” in your equivalence table, you have stated that both are biocompatible. You have not stated that they are biologically equivalent.

The reviewer will ask: But are they equivalent in their biological behavior? Do they interact with tissue the same way? Do they produce the same biological response?

If you cannot answer these questions with evidence, your equivalence claim is vulnerable.

When Biological Equivalence Cannot Be Demonstrated

Sometimes the honest conclusion is that biological equivalence cannot be demonstrated.

This happens when material or contact differences are significant enough that biological interaction cannot reasonably be considered equivalent.

In these cases, attempting to force an equivalence claim creates more problems than it solves.

I reviewed a case where a manufacturer tried to claim equivalence between a metal implant and a polymer implant. Same intended purpose. Similar mechanical function. Completely different biological interface.

The manufacturer tried to argue equivalence based on similar clinical outcomes. The reviewer rejected this immediately because the biological interaction mechanisms were fundamentally different.

The manufacturer would have been better served by acknowledging that equivalence could not be demonstrated and building a clinical evaluation based on their own device’s clinical data and relevant literature.

Forcing equivalence where it does not exist weakens your entire clinical evaluation.

Integration with the Clinical Evaluation

Biological equivalence is not an isolated technical exercise. It integrates directly with your clinical evaluation strategy.

If biological equivalence cannot be clearly demonstrated, the clinical data from your equivalent device may not be applicable to your device. This affects:

• What literature is relevant for your device
• What clinical data can be used to support safety and performance
• What gaps exist in your clinical evidence
• What PMCF activities are needed

This is why biological equivalence matters beyond just satisfying a checklist requirement. It determines whether your entire equivalence-based clinical evaluation is valid.

A weak biological equivalence demonstration undermines your clinical evaluation even if your technical and clinical equivalence sections are strong.

All three pillars must stand.

Practical Steps Forward

If you are preparing an equivalence demonstration, address biological equivalence as deliberately as you address technical and clinical equivalence.

Create a specific section for biological equivalence. Do not bury it in the technical comparison.

Compare materials, contact type, contact duration, tissue interface characteristics explicitly. Document similarities. Address differences with evidence.

Do not rely on ISO 10993 compliance alone. Provide comparative biological analysis.

If you have material or contact differences, get your biocompatibility expert involved early. They need to assess whether comparative biological data is needed and what that data should include.

If you cannot demonstrate biological equivalence clearly, reconsider whether equivalence is the right strategy for your clinical evaluation.

The goal is not to force equivalence through creative writing. The goal is to demonstrate clearly that your device and the equivalent device are truly equivalent in all relevant characteristics, including biological behavior.

When this demonstration is solid, the equivalence claim is defensible. When it is not, the entire clinical evaluation is at risk.

What Happens Next

The three-pillar framework for equivalence is not new. It has been in MDR Annex XIV since the regulation came into force. Yet biological equivalence remains the weakest pillar in most demonstrations I review.

This creates unnecessary delays, major non-conformities, and sometimes complete rejection of equivalence claims that could have been valid with proper biological equivalence documentation.

The solution is not complex. It requires attention, structured comparison, and evidence-based demonstration of biological similarity.

But it requires acknowledging that biological equivalence is not automatic just because both devices are biocompatible.

When manufacturers understand this, when they address biological equivalence with the same rigor they apply to technical and clinical equivalence, the equivalence demonstration becomes defensible.

Until then, this forgotten third pillar will continue to collapse under regulatory review.

Peace,
Hatem
Clinical Evaluation Expert for Medical Devices
Follow me for more insights and practical advice.